Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | PGR | P06401 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 4/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638232 | 0.84 | STS (0.51) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL31508411 | 0.83 | ESR1 (0.50) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL1656677 | 0.83 | ESR1 (0.63) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL4645148 | 0.83 | ESR1 (0.63) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL13336961 | 0.82 | LMNA (0.50) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL6569494 | 0.82 | ESR1 (0.40) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL12269944 | 0.82 | STS (0.53) | ESR1NR3C1LMNAPGRCYP3A4 | |
| SCHEMBL31508300 | 0.82 | STS (0.53) | ESR1NR3C1LMNAPGRCYP3A4 | |
| SCHEMBL11688794 | 0.81 | ESR1 (0.70) | ESR1ESR2NR3C1LMNAPGR | |
| SCHEMBL12269980 | 0.81 | STS (0.59) | ESR1NR3C1LMNAPGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305694-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | SRI International (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1847548-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1405860-B1 | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | STANFORD RES INST INT (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6747018-B2 | TREATMENT OF ESTROGEN-DEPENDENT DISORDERS; PREFERRED COMPOUNDS HAVE 1,3,5-ESTRATRIENE NUCLEUS, AND ARE SUBSTITUTED AT C-17 OR C-11 WITH MOLECULAR MOIETY WHICH RENDERS COMPOUNDS EFFECTIVE TO BLOCK BINDING OF ESTROGEN TO ITS RECEPTOR | SRI INTERNATIONAL | 2004-06-08 | — | — | US | disclosed |
| EP-1405860-A1 | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | SRI INTERNATIONAL (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2003-08-14 | — | — | US | disclosed |
| EP-1310509-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6548491-B2 | For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated | SRI INTERNATIONAL | 2003-04-15 | — | — | US | disclosed |
| US-6503896-B1 | 17-Desoxy-1,3,5-estratriene derivatives; postmenopause, osteoporosis, central nervous system disorders; anticarcinogenic and hypotensive agents | SRI INTERNATIONAL | 2003-01-07 | — | — | US | disclosed |
| US-6455517-B1 | FOR THERAPY OF CONDITIONS OR DISEASES THAT ARE ESTROGEN-DEPENDENT, I.E., ARE ESTROGEN-INDUCED OR ESTROGEN-STIMULATED | SRI INTERNATIONAL | 2002-09-24 | — | — | US | disclosed |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-6281205-B1 | 1,3,5(10)-ESTRATRIENE NUCLEUS, SUBSTITUTED AT THE C-17 POSITION WITH AN AMINE AND ETHER-CONTAINING GROUP | SRI INTERNATIONAL | 2001-08-28 | — | — | US | disclosed |
| EP-1056768-A2 | NOVEL ANTI-ESTROGENIC STEROIDS, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 2000-12-06 | — | — | EP | disclosed |
| US-6054446-A | 17-SUBSTITUTED-17-DESOXY-1,3,5-ESTRATRIENES. | SRI INTERNATIONAL (US) | 2000-04-25 | — | — | US | disclosed |
| US-6046186-A | ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | SRI INTERNATIONAL (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999033859-A2 | NOVEL ANTI-ESTROGENIC STEROIDS, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5861388-A | TREATMENT OF ESTROGEN DEPENDENT DISORDERS AS FOR EXAMPLEBREAST CANCER | SRI INTERNATIONAL (US) | 1999-01-19 | — | — | US | disclosed |
| US-5763432-A | TREATMENT OF ESTROGEN-DEPENDENT DISORDERS | SRI INTERNATIONAL (US) | 1998-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885NR3C1 23/4885 |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | ESR1 5/4885ESR2 2/4885NR3C1 26/4885 |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | ESR1 5/4885ESR2 2/4885NR3C1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.